HEYL and COVID-19: Also, we found that the mCpG rates were ranged from 11.15% to 75.0% in COVID-19 patients vs. 14%-75% in control healthy subjects compared to full methylated HeyL promoter in reference sequence (Figures 2(b) and 2(c)).